“The advisory vote added Semax to the 503A list or approved it.”

01 · Answer

Misleading

RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.

What kind of evidence this is

Regulatory or product record. This answer uses an official regulator record or a specific product label.

What this answer covers

The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.

Question type

Approval and status. Whether a specific product has an approval or another official status.